What a talar OCD actually is

Seeing the words 'osteochondral defect of the talus' on an MRI report can be alarming — especially when you cannot remember a specific injury that might have caused it. The finding is more straightforward than the terminology suggests.

The talus is the bone that forms the lower half of your ankle joint. Its domed upper surface is covered in articular cartilage — the smooth, load-bearing tissue that allows the ankle to move without friction. An osteochondral defect (OCD) is a localised area where both that cartilage surface and the bone immediately beneath it have been damaged, leaving a focal weak spot on the dome.

These lesions are considerably more common than most patients expect. Studies find them in up to 69% of ankle fractures and 70% of significant sprains — yet many are detected only months or years later, after a period of nagging ache, stiffness, or intermittent swelling that never quite resolved. Roughly 83% of talar OCDs occur on the inner (medial) side of the dome. Medial lesions tend to be larger and deeper than those on the outer side, and they are less often linked to a single memorable trauma — which is why patients with a medial lesion so frequently say, 'I can't think what I actually did to it.'

Symptoms — a dull ache deep in the ankle, catching or giving way, swelling after activity — often creep in gradually rather than arriving with a definitive injury moment. The MRI confirms the structural picture, but it does not tell the full clinical story on its own; asymptomatic talar OCDs exist, and the severity of a patient's symptoms does not always mirror how the lesion looks on the scan. The MRI is one important input; how the ankle behaves day to day matters equally.

Reading your Hepple MRI stage

The Hepple classification is the staging language your radiologist and orthopaedic surgeon use to map precisely what the MRI is showing. Knowing where your lesion sits makes the report genuinely legible.

Stage I records bone marrow oedema only — the bone beneath the cartilage is bruised, but the cartilage surface itself remains intact. This is the most stable finding.

Stages IIa and IIb indicate that a hairline fracture has developed within the subchondral bone, with cartilage injury above it. Stage IIa carries surrounding marrow oedema; Stage IIb has the same fracture line without oedema. Both are still stable — the fragment has not separated from its bed.

Stages I through IIb together form the conservative zone, where immobilisation, protected weight-bearing, and rehabilitation are reasonable first steps.

Stage III is the critical inflection point. The fragment is detached but has not moved. The defining MRI feature is the rim sign — a bright, high-T2 fluid line running beneath the fragment, confirming that the bond between fragment and parent bone has broken even though nothing has shifted yet.

Stage IV means the fragment has displaced out of position. Stage V adds subchondral cyst formation — fluid-filled cavities beneath the defect, typically ≥5 mm, that erode the bony support. A defect measuring ≥5 mm in width or depth at either of these stages signals structural instability. Both Stages IV and V almost universally call for surgical discussion.

What the non-surgical pathway looks like

Conservative management is the right starting point for Stage I, IIa, and IIb lesions — and, regardless of stage, for skeletally immature patients whose bone retains a meaningful capacity for spontaneous remodelling.

The programme is active rather than passive. A period in a walking boot (typically four to six weeks of protected weight-bearing) is followed by supervised physiotherapy focused on ankle stability, proprioception, and graduated load tolerance. Anti-inflammatory medication helps settle reactive symptoms; some consultants add a platelet-rich plasma injection to support the biological environment. The whole course usually spans three to six months before a structured clinical review.

A 2023 systematic review of 868 patients — median follow-up 37 months — puts the pooled clinical success rate at 45%. That figure is worth stating plainly: roughly half of patients managed non-surgically do not achieve satisfactory symptom resolution.

The imaging story adds a crucial nuance. MRI showed the lesion structurally unchanged in 84% of those same patients — yet that stability did not translate into clinical improvement. A stable scan is not a healed ankle: the defect has not grown, but that says nothing about how the joint functions day to day. Conversely, 9% showed osteoarthritic change on X-ray and 12% showed focal deterioration on MRI, which is why repeat imaging at agreed intervals is built into the pathway as a standard checkpoint rather than a sign that something has gone wrong.

When surgery enters the conversation

Several clinical markers shift the pathway from watchful management to surgical planning — and understanding them explains why that conversation arises at different points for different patients.

Stage III warrants specialist discussion even before conservative care has run its full course. The rim sign identifies a fragment that is detached but not yet displaced; continued loading carries a real risk of it shifting. Surgeons do not always intervene immediately at this stage, but leaving a Stage III lesion without orthopaedic review for the full three-to-six month window is generally inadvisable given that displacement risk.

Stages IV and V rarely allow further delay. A displaced fragment and subchondral cyst formation almost universally require surgical intervention; the question at those stages is technique selection, not whether to operate.

Lesion size provides the most precisely evidence-grounded threshold. Research across 105 lesions showed that bone marrow stimulation (microfracture) succeeded in virtually all cases below 15 mm average diameter, yet only approximately 3% of lesions at or above that threshold improved with microfracture alone. On MRI reports, this corresponds to a cross-sectional area cut-off of 150 mm² — a specific figure clinicians use when weighing the first surgical option against more involved cartilage restoration techniques.

Failed conservative care after three to six months of a structured programme is the most common route to surgical planning for Stage II–III lesions.

Two further factors can tilt the decision even when stage and size fall near the threshold. Biomechanical modelling of the talar dome suggests that posteromedial, mid-posterior, and anterolateral zones sustain the greatest stiffness loss for a given defect size, potentially increasing the urgency of intervention in those areas. Separately, whole-leg standing radiography is increasingly part of specialist workup — particularly for revision cases — because coronal malalignment independently predicts lesion location and informs both technique choice and longer-term planning.

Treatment options from injection to surgery

Treatment options for talar OCD run from minimally invasive to surgical, and the choice between them depends primarily on lesion stage, size, and how far conservative management has progressed.

Injectable collagen scaffold (ChondroFiller). For eligible lesions — typically Stage I–IIb, defect diameter below 15 mm, in patients who have not fully responded to conservative measures — ChondroFiller offers a single-stage, ultrasound-guided outpatient injection. The scaffold is placed directly into the defect, where it supports matrix-induced chondrogenesis by providing a structure into which the patient's own progenitor cells can migrate. This route suits patients who want to avoid theatre; suitability is confirmed at specialist assessment.

Bone marrow stimulation (microfracture / nano-fracture). The most established arthroscopic option for smaller lesions. Results are durable below the 15 mm average diameter threshold but fall sharply above it, which often moves the conversation towards one of the cartilage restoration techniques below.

OATS (osteochondral autograft transfer). Cylindrical plugs of healthy cartilage and subchondral bone are harvested from a lower-load region of the joint and transferred into the defect. Published series report approximately 90% patient satisfaction — the highest of the surgical options — though the technique adds donor-site morbidity at the harvest zone.

AMIC (autologous matrix-induced chondrogenesis). Combines marrow stimulation with a collagen membrane to support and retain the repair tissue. At medium-to-long follow-up, functional outcomes are comparable or superior to mosaicplasty without requiring a separate harvest site.

No large randomised controlled trial has directly compared these approaches head-to-head; individual suitability requires specialist assessment.

Getting an assessment at the London Cartilage Clinic

A specialist assessment for talar OCD typically brings together three things in one appointment: a detailed history of symptoms and mechanism (including whether there has been repeated ankle instability), a functional examination of the ankle and lower limb, and a structured review of any imaging already performed. If an MRI has not yet been obtained, or if the existing scan was acquired at low field strength, a dedicated ankle MRI is usually arranged at this stage.

From that combined picture — Hepple stage, defect dimensions, instability markers on MRI, and whole-leg alignment where relevant — the clinician can map a specific treatment recommendation rather than a generic one. The difference between a Stage IIb lesion of 10 mm in a well-aligned limb and a Stage III lesion of 18 mm with rim sign and varus malalignment is material; those two patients leave the consultation with meaningfully different plans.

For London and commuter-belt patients weighing the injectable collagen scaffold route, Liquid Cartilage™ (ChondroFiller injection) is delivered at the London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads the programme. Initial assessments can be booked at londoncartilage.com.

1. [1] Lower limb malalignment on whole-leg radiography predicts medial or lateral talar OCD location. (2025). https://doi.org/10.1016/j.ocarto.2025.100707 https://doi.org/10.1016/j.ocarto.2025.100707
2. [2] Surgical Treatments of Talar Osteochondral Lesion: Long-term Follow-up of Return to Sport and Patient-Reported Outcome Measures. (2019). https://doi.org/10.1177/2473011419s00375 https://doi.org/10.1177/2473011419s00375
3. [3] In silico assessment of talus osteochondral lesion size and location on biomechanical load distribution. (2025). https://doi.org/10.5152/j.aott.2025.25444 https://doi.org/10.5152/j.aott.2025.25444
4. [4] Comparison of autologous matrix-induced chondrogenesis and mosaicplasty in treatment of osteochondral defects of the talus. (2024). https://doi.org/10.5152/j.aott.2024.23001 https://doi.org/10.5152/j.aott.2024.23001
5. [5] Results of the AMIC® method in patients operated on for an osteochondral lesion of the talar dome at mean follow-up 34 months. (2024). https://doi.org/10.1016/j.otsr.2024.104020 https://doi.org/10.1016/j.otsr.2024.104020